Status:
NOT_YET_RECRUITING
Neoadjuvant Treatment vs Upfront Surgery for Left-Sided Pancreatic Cancer
Lead Sponsor:
Helsinki University Central Hospital
Collaborating Sponsors:
Oulu University Hospital
Conditions:
Pancreatic Cancer Resectable
Eligibility:
All Genders
18-85 years
Phase:
PHASE3
Brief Summary
Pancreatic cancer is one of the most treatment resistant malignancies, often diagnosed at a late stage and associated with poor survival. The 5-year overall survival rate remains around 10%. Prognosis...
Detailed Description
This is a multicenter, open-label, randomized phase III trial evaluating whether neoadjuvant chemotherapy improves overall survival in patients with resectable left-sided (body/tail) pancreatic cancer...
Eligibility Criteria
Inclusion
- Resectable left pancreatic cancer according to NCCN criteria
- Written and informed consent
- Age \> 18y
- ECOG 0-2
- Fit for surgery
- Fit for neoadjuvant chemotherapy
Exclusion
- ECOG \> 2
- Histology other than ductal adenocarcinoma
- Unable to give written consent
- \< 18y
Key Trial Info
Start Date :
September 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 31 2030
Estimated Enrollment :
381 Patients enrolled
Trial Details
Trial ID
NCT07155629
Start Date
September 1 2025
End Date
August 31 2030
Last Update
September 4 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Helsinki University Central Hospital
Helsinki, Finland, 00290
2
Oulu University Hospital
Oulu, Finland, 90220